Intrahepatic metastases may be specific to hepatocellular carcinoma due to the coagulation and fibrinolytic systems (Review)
- Authors:
- Xuemei Li
- Baohong Gu
- Bofang Wang
- Zedong Feng
- Yanling Ma
- Haiyuan Li
- Alexandra Lucas
- Hao Chen
-
Affiliations: The Second Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P.R. China, Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA, Department of Tumor Surgery, Lanzhou University Second Hospital, Lanzhou, Gansu 730000, P.R. China - Published online on: October 9, 2020 https://doi.org/10.3892/or.2020.7800
- Pages: 2345-2352
This article is mentioned in:
Abstract
 |
 |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Villanueva A: Hepatocellular carcinoma. N Engl J Med. 380:1450–1462. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kulik L and El-Serag HB: Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 56:477–491. 2019. View Article : Google Scholar | |
|
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, Schwartz M, Han G, Izzo F, Chen M, et al: The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 62:440–451. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann Surg. 261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kanoh Y: Coagulation and fibrinolytic system. Nihon Rinsho. 74 (Suppl 4):S301–S305. 2016.(In Japanese). | |
|
Tsai MC, Yen YH, Chang KC, Hung CH, Chen CH, Lin MT and Hu TH: Elevated levels of serum urokinase plasminogen activator predicts poor prognosis in hepatocellular carcinoma after resection. BMC Cancer. 19:11692019. View Article : Google Scholar : PubMed/NCBI | |
|
Wei L, Lun Y, Zhou X, He S, Gao L, Liu Y, He Z, Li B and Wang C: Novel urokinase-plasminogen activator inhibitor SPINK13 inhibits growth and metastasis of hepatocellular carcinoma in vivo. Pharmacol Res. 143:73–85. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zacharski LR: Anticoagulants in cancer treatment: Malignancy as a solid phase coagulopathy. Cancer Lett. 186:1–9. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Lip GY, Chin BS and Blann AD: Cancer and the prothrombotic state. Lancet Oncol. 3:27–34. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Zacharski LR, Wojtukiewicz MZ, Costantini V, Ornstein DL and Memoli VA: Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost. 18:104–116. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Falanga A, Marchetti M and Vignoli A: Coagulation and cancer: Biological and clinical aspects. J Thromb Haemost. 11:223–233. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Thodiyil PA and Kakkar AK: Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 87:1076–1077. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nadir Y: Decreasing tumor growth and angiogenesis by inhibition of coagulation. Semin Thromb Hemost. 45:622–628. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sun H, Cao D, Liu Y, Wang H, Ke X and Ci T: Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer. Biomater Sci. 6:2172–2188. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Furie B and Furie BC: The molecular basis of blood coagulation. Cell. 53:505–518. 1988. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Q, Huang T, Wang YF, Zhou XB, Liang LJ and Peng BG: Role of tissue factor in hepatocellular carcinoma genesis, invasion and metastasis. Chin Med J (Engl). 124:3746–3751. 2011.PubMed/NCBI | |
|
Huang SZ, Wei MN, Huang JR, Zhang ZJ, Zhang WJ, Jiang QW, Yang Y, Wang HY, Jin HL, Wang K, et al: Targeting TF-AKT/ERK-EGFR pathway suppresses the growth of hepatocellular carcinoma. Front Oncol. 9:1502019. View Article : Google Scholar : PubMed/NCBI | |
|
Dupuy E, Hainaud P, Villemain A, Bodevin-Phèdre E, Brouland JP, Briand P and Tobelem G: Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol. 38:793–802. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and Wong J: Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res. 9:5339–5345. 2003.PubMed/NCBI | |
|
Panasiuk A, Zak J, Panasiuk B and Prokopowicz D: Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis. Blood Coagul Fibrinolysis. 18:739–744. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M, Wan Y, Tang J, Li H, Yu G, Zhu J, Ji S, Guo H, Zhang N, Li W, et al: Depletion of tissue factor suppresses hepatic metastasis and tumor growth in colorectal cancer via the downregulation of MMPs and the induction of autophagy and apoptosis. Cancer Biol Ther. 12:896–907. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Tian ML, Yu G, Liu YC, Wang X, Zhang J, Ji SQ, Zhu J, Wan YL and Tang JQ: Hyperthermia synergizes with tissue factor knockdown to suppress the growth and hepatic metastasis of colorectal cancer in orthotopic tumor model. J Surg Oncol. 106:689–695. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zerbib P, Grimonprez A, Corseaux D, Mouquet F, Nunes B, Petersen LC, Susen S, Ung A, Hebbar M, Pruvot FR, et al: Inhibition of tissue factor-factor VIIa proteolytic activity blunts hepatic metastasis in colorectal cancer. J Surg Res. 153:239–245. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Neaud V, Hisaka T, Monvoisin A, Bedin C, Balabaud C, Foster DC, Desmoulière A, Kisiel W and Rosenbaum J: Paradoxical pro-invasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J Biol Chem. 275:35565–35569. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai MC, Chen KD, Wang CC, Huang KT, Wu CH, Kuo IY, Chen LY, Hu TH, Goto S, Nakano T, et al: Factor VII promotes hepatocellular carcinoma progression through ERK-TSC signaling. Cell Death Discov. 1:150512015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen KD, Wang CC, Tsai MC, Wu CH, Yang HJ, Chen LY, Nakano T, Goto S, Huang KT, Hu TH, et al: Interconnections between autophagy and the coagulation cascade in hepatocellular carcinoma. Cell Death Dis. 5:e12442014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CC, Wu CH, Chen LY, Tsai MC, Elsarawy AM and Huang KT: Coagulation factor VII gene polymorphisms are not associated with the occurrence or the survival of hepatocellular carcinoma: A report of 37 cases. Cancer Biol Med. 15:275–281. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Y, Wang X, Cheng S, Du J, Deng Z, Zhang Y, Liu Q, Gao J, Cheng B and Ling C: Diosgenin induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Oncol Rep. 33:693–698. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuang M, Xin G, Wei Z, Li S, Xing Z, Ji C, Du J, Niu H and Huang W: Dihydrodiosgenin inhibits endothelial cell-derived factor VIII and platelet-mediated hepatocellular carcinoma metastasis. Cancer Manag Res. 11:4871–4882. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Yoo BK, Chen D, Su ZZ, Gredler R, Yoo J, Shah K, Fisher PB and Sarkar D: Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res. 70:3249–3258. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Srivastava J, Siddiq A, Emdad L, Santhekadur PK, Chen D, Gredler R, Shen XN, Robertson CL, Dumur CI, Hylemon PB, et al: Astrocyte elevated gene-1 promotes hepatocarcinogenesis: Novel insights from a mouse model. Hepatology. 56:1782–1791. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 44:139–266. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM and Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 284:67–68. 1980. View Article : Google Scholar : PubMed/NCBI | |
|
Sun BS, Dong QZ, Ye QH, Sun HJ, Jia HL, Zhu XQ, Liu DY, Chen J, Xue Q, Zhou HJ, et al: Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology. 48:1834–1842. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cao X, Zhang L, Shi Y, Sun Y, Dai S, Guo C, Zhu F, Wang Q, Wang J, Wang X, et al: Human tumor necrosis factor (TNF)-alpha-induced protein 8-like 2 suppresses hepatocellular carcinoma metastasis through inhibiting Rac1. Mol Cancer. 12:1492013. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai JP, Hsiao PC, Yang SF, Hsieh SC, Bau DT, Ling CL, Pai CL and Hsieh YH: Licochalcone a suppresses migration and invasion of human hepatocellular carcinoma cells through downregulation of MKK4/JNK via NF-κB mediated urokinase plasminogen activator expression. PLoS One. 9:e865372014. View Article : Google Scholar : PubMed/NCBI | |
|
Weng CJ, Chou CP, Ho CT and Yen GC: Molecular mechanism inhibiting human hepatocarcinoma cell invasion by 6-shogaol and 6-gingerol. Mol Nutr Food Res. 56:1304–1314. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KH, Choi EY, Hyun MS, Jang BI, Kim TN, Lee HJ, Eun JY, Kim HG, Yoon SS, Lee DS, et al: Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: A potential therapeutic target. Clin Exp Metastasis. 25:89–96. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sun H and Liu GT: Inhibitory effect of anti-hepatitis drug bicyclol on invasion of human hepatocellular carcinoma MHCC97-H cells with high metastasis potential and its relative mechanisms. J Asian Nat Prod Res. 11:576–583. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Blasi F and Carmeliet P: uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Biol. 3:932–943. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sakakibara T, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K and Nakao A: Plasminogen activator inhibitor-1 as a potential marker for the malignancy of colorectal cancer. Br J Cancer. 93:799–803. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou L, Jin Y, Cui QC, Jin KM, Zhou WX and Xing BC: Low expression of PAI-2 as a novel marker of portal vein tumor thrombosis and poor prognosis in hepatocellular carcinoma. World J Surg. 37:608–613. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Weng CJ, Tsai CM, Chen YC, Hsieh YH, Lin CW, Liu YF, Su SC, Chen MK and Yang SF: Evaluation of the association of urokinase plasminogen activator system gene polymorphisms with susceptibility and pathological development of hepatocellular carcinoma. Ann Surg Oncol. 17:3394–3401. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Chen H, Peng H, Liu W, Sun Y, Su N, Tang W, Zhang X, Wang J, Cui L, Hu P, et al: Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery. 158:1704–1713. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, et al: Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE. Transl Oncol. 8:273–278. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang X, Wang N, Li H, Liu M, Cao F, Yu X, Zhang J, Tan Y, Xiang L and Feng Y: Up-Regulation of PAI-1 and down-regulation of uPA are involved in suppression of invasiveness and motility of hepatocellular carcinoma cells by a natural compound berberine. Int J Mol Sci. 17:5772016. View Article : Google Scholar : PubMed/NCBI | |
|
Jin Y, Liang ZY, Zhou WX and Zhou L: Plasminogen activator inhibitor 2 (PAI2) inhibits invasive potential of hepatocellular carcinoma cells in vitro via uPA- and RB/E2F1-related mechanisms. Hepatol Int. 13:180–189. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM and Poon RT: Biology of hepatocellular carcinoma. Ann Surg Oncol. 15:962–971. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo A, Shinoda M, Ariizumi S, Kumamoto T, Katayama M, Otsubo T, Endo I, Kitagawa Y, Tanabe Y, Yamamoto M, et al: Des-gamma-carboxy prothrombin affects the survival of HCC patients with marginal liver function and curative treatment: ACRoS1402. J Cancer Res Clin Oncol. 2020.(Epub ahead of print). View Article : Google Scholar | |
|
Li Y and Chen J: Serum des-gamma-carboxy prothrombin for diagnosis of adult primary cancer in liver. J Coll Physicians Surg Pak. 29:972–976. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cai Z, Chen G, Zeng Y, Dong X, Li Z, Huang Y, Xin F, Qiu L, Xu H, Zhang W, et al: Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma. Clin Cancer Res. 25:5284–5294. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S and Makuuchi M: Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol. 22:969–975. 2003.PubMed/NCBI | |
|
Suzuki M, Shiraha H, Fujikawa T, Takaoka N, Ueda N, Nakanishi Y, Koike K, Takaki A and Shiratori Y: Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem. 280:6409–6415. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Gao FJ, Cui SX, Chen MH, Cheng YN, Sun LR, Ward SG, Kokudo N, Tang W and Qu XJ: Des-gamma-carboxy prothrombin increases the expression of angiogenic factors in human hepatocellular carcinoma cells. Life Sci. 83:815–820. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Yue P, Gao ZH, Xue X, Cui SX, Zhao CR, Yuan Y, Yin Z, Inagaki Y, Kokudo N, Tang W and Qu XJ: Des-γ-carboxyl prothrombin induces matrix metalloproteinase activity in hepatocellular carcinoma cells by involving the ERK1/2 MAPK signalling pathway. Eur J Cancer. 47:1115–1124. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Murata K and Sakamoto A: Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: A possible mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 33:1149–1155. 2008.PubMed/NCBI | |
|
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y and Sakamoto A: Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol. 36:161–170. 2010.PubMed/NCBI | |
|
Mizuta T, Ozaki I, Eguchi Y, Yasutake T, Kawazoe S, Fujimoto K and Yamamoto K: The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: A pilot study. Cancer. 106:867–872. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T and Omata M: Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology. 40:243–251. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Shi CS, Shi GY, Hsiao HM, Kao YC, Kuo KL, Ma CY, Kuo CH, Chang BI, Chang CF, Lin CH, et al: Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood. 112:3661–3670. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K and Sugimachi K: Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology. 21:1285–1290. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, Wu CC, Wu CH, Ho YS, Yang YY and Chang YJ: Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. Ann Surg Oncol. 17:3379–3385. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hasegawa M, Nakoshi Y, Iino T, Sudo A, Segawa T, Maeda M, Yoshida T and Uchida A: Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol. 36:240–245. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xue YH, Zhang XF, Dong QZ, Sun J, Dai C, Zhou HJ, Ren N, Jia HL, Ye QH and Qin LX: Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology. 52:2012–2022. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Liotta LA and Kohn E: Anoikis: Cancer and the homeless cell. Nature. 430:973–974. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YN, Koo KH, Sung JY, Yun UJ and Kim H: Anoikis resistance: An essential prerequisite for tumor metastasis. Int J Cell Biol. 2012:3068792012. View Article : Google Scholar : PubMed/NCBI | |
|
Frisch SM and Francis H: Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol. 124:619–626. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Cheng SL, Bian K, Wang L, Zhang X, Yan B, Jia LT, Zhao J, Gammoh N, Yang AG and Zhang R: MicroRNA-26a promotes anoikis in human hepatocellular carcinoma cells by targeting alpha5 integrin. Oncotarget. 6:2277–2289. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jia Q, Xue T, Zhang Q, Cheng W, Zhang C, Ma J, Bu Y, Yu S and Liu Q: CCN3 is a therapeutic target relating enhanced stemness and coagulation in hepatocellular carcinoma. Sci Rep. 7:138462017. View Article : Google Scholar : PubMed/NCBI | |
|
Ishikawa T, Kitano H, Mamiya A, Kokubun S and Hidai C: The first EGF domain of coagulation factor IX attenuates cell adhesion and induces apoptosis. Biosci Rep. 36:e003402016. View Article : Google Scholar : PubMed/NCBI | |
|
Versteeg HH, Spek CA, Richel DJ and Peppelenbosch MP: Coagulation factors VIIa and Xa inhibit apoptosis and anoikis. Oncogene. 23:410–417. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Das S and Johnson DB: Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 7:3062019. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389:2492–2502. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, et al: Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 553:91–95. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher DW: MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 352:227–231. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Li N, Wang J, Zhang N, Zhuang M, Zong Z, Zou J, Li G, Wang X, Zhou H, Zhang L and Shi Y: Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother. 67:271–283. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang J, Zhang N, Sun H, Su L, Zhang C, Xu H, Feng J, Wang M, Chen J, Liu L, et al: Disruption of SIRT7 increases the efficacy of checkpoint inhibitor via MEF2D regulation of programmed cell Death 1 Ligand 1 in hepatocellular carcinoma cells. Gastroenterology. 158:664–678.e24. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Liu M, Sun H, Feng Y, Xu L, Chan AWH, Tong JH, Wong J, Chong CCN, Lai PBS, et al: Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut. 67:931–944. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J, et al: ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell. 26:331–343. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ and Karin M: Preclinical models for studying NASH-Driven HCC: How useful are they? Cell Metab. 29:18–26. 2019. View Article : Google Scholar : PubMed/NCBI |
